BioSpace News Archive

Allan Gobbs is managing partner at ATEM Capital, a New York–based life sciences venture firm focused on biotechnology, AI-powered precision medicine and health automation. He is also executive chairman and co-founder of PGxAI, a Palo Alto-based pharmacogenetics startup leveraging AI and real-world data to advance ultra-precision medicine. In addition, he serves as CEO and chairman of YCare, a digital health platform that integrates home-based care for providers and payors.

Analysts believe that Gilead’s new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA removes CAR T guardrails; AbbVie snaps up Capstan for $1.2B to end first half; and psychedelics take off again with data from Compass and Beckley.

California’s life sciences manufacturing jobs dipped 3.7% in 2024, according to a new Biocom California report. Still, several companies made—and continuing making—significant manufacturing investments in the state as key trends shape the discipline.

The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone.”

Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of limitations” to more than three years.

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called bluebird bio? We wanted to know.

As an office of the executive branch, the Department of Health and Human Services “does not have the authority” to implement sweeping changes to the structure of the agency as created by Congress, a judge wrote.

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.